Melola Discovery

← Melola Discovery

Jurnal SINTA 1

Review Article and Clinical Experience: Hypertension in Diabetic Nephropathy. The Five “Satan Circles”, DHA-LiCOAR, the Roles of Valsartan

Folia Medica Indonesiana · Vol. 43 No. 2 (2007)

ISSN
2355-8393, 2599-056X
Terbit
2007-04-01
Penerbit
Airlangga University
Bahasa
en

Abstrak

On the basis of clinical experiences, 5 (five) “Satan Vicious Circles” in diabetic nephropathy (DN) are summarized. These vicious circles should be well recognized to understand the pathogenesis of DN, and to perform its rationale treatment. The 1st “Satan Circle” hypertension –– proteinuria –– glomerular injury –– and then to hypertension again. The 2nd “Satan Circle” GLUT-1 –– glucose –– TGF- β –– and then to GLUT-1 again. The 3rd “Satan Circle” AII –– TGF- β –– PAI-1 –– and then to AII again. The 4th “Satan Circle” AII –– PKC –– AI –– and then to AII again. The 5th “Satan Circle” or the “Deadly Satan Circle” (frequently happens in hemodyalized-patients). Dialysate, Membrane, and AOPP these three components altogether stimulate the production of cytokines (VCAM1, MCP1, etc) –– NADPH oxidase –– increased ROS and RONS production –– activated NFkB/API/MAPK –– and then to cytokines (VCAM1, MCP1, etc) again. ROS and RONS also stimulate the production of MMP9. On the basis of clinical experiences in Surabaya, “DHA-LiCOAR” (Diabetes, Hypertension, Albuminuria – Lipid, Cigarette, Obesity, Antiplatelet, Renal replacement therapy) can be used as practical guideline for the treatment of patients with DN. MARVAL and VALUE are the two landmark studies of valsartan which favours microalbuminuria reduction of patients with DN and lower incidence of new-onset of diabetes, respectively. The results of MARVAL indicate a blood pressure-independent antiproteinuric effects of valsartan (blood pressure-independent effect). Compared with amlodipine, valsartan significantly lowered urinary albumin excretion rate of T2DM with microalbuminuria (-8% in amlodipine vs -44% in valsartan treated, p < 0.001). At 24-weeks, valsartan treated patients showed 29.9% reversion to normoalbuminuria compared with 14.5% in amlodipine treated patients (p < 0.001). In the VALUE study, valsartan showed 23% risk reduction of the new-onset diabetes (p < 0.0001). There was no significant difference in the outcomes in hypertensive patients at high cardiovascular risk treated with regiments based on valsartan or amlodipine. Valsartan (a highlyselective ARB) improved “DHA” (the three essential components), and hence this ARB is in favour of the treatment of patients with diabetic nephropathy.

Kata kunci

Jaringan kolaborasi para penulis

8 penulis · 16 tautan kepenulisan bersama · 7 lintas organisasi

Arahkan kursor atau ketuk sebuah nama untuk menyorot rekan penulisnya. Klik dua kali untuk membuka halaman penulis.

  • Universitas Airlangga
  • University of Brawijaya
  • Rumah Sakit Umum Pusat Dr. Sardjito
  • Afiliasi tidak diketahui
  • Organisasi berbeda
  • Organisasi sama
  • Afiliasi tidak diketahui
  • Garis lebih tebal = lebih banyak artikel bersama · lingkaran lebih besar = lebih banyak artikel
Tampilkan sebagai tabel
Rekan penulisOrganisasiArtikel bersama
Agung Sindu PranotoUniversitas Airlangga1
Hermina NovidaUniversitas Airlangga1
Jongky Hendro PrayitnoAfiliasi tidak diketahui1
Adeodatus Yuda HandayaRumah Sakit Umum Pusat Dr. Sardjito1
Djanggan SargowoUniversity of Brawijaya1
Diana LyrawatiUniversity of Brawijaya1
Mohammad Aris WidodoUniversity of Brawijaya1

Afiliasi berasal dari OpenAlex; metadata OAI-PMH jurnal tidak memuatnya. Penulis tanpa ID OpenAlex dicocokkan berdasarkan nama, sehingga dua orang bisa tergabung atau satu orang bisa terpisah.

Sumber metadata: OpenAlex API (jurnal SINTA, ADR 0048) https://openalex.org/S4210179714, pertama di-harvest 19 Nov 2026, terakhir terlihat 19 Nov 2026.
Metadata asli (oai_dc)
<oai_dc:dc xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:oai_dc="http://www.openarchives.org/OAI/2.0/oai_dc/"><dc:title xml:lang="en">Review Article and Clinical Experience: Hypertension in Diabetic Nephropathy. The Five “Satan Circles”, DHA-LiCOAR, the Roles of Valsartan</dc:title><dc:creator>Askandar Tjokroprawiro</dc:creator><dc:subject>diabetic nephropathy</dc:subject><dc:subject>hypertension</dc:subject><dc:subject>proteinuria</dc:subject><dc:subject>vicious circle</dc:subject><dc:subject>valsartan</dc:subject><dc:subject>angiotensin II</dc:subject><dc:subject>TGF-beta</dc:subject><dc:subject>plasminogen activator inhibitor-1</dc:subject><dc:subject>protein kinase C</dc:subject><dc:subject>albuminuria</dc:subject><dc:subject>hemodialysis</dc:subject><dc:subject>dialysate</dc:subject><dc:subject>oxidative stress</dc:subject><dc:subject>NADPH oxidase</dc:subject><dc:subject>cytokines</dc:subject><dc:subject>values</dc:subject><dc:subject>amlodipine</dc:subject><dc:subject>microalbuminuria</dc:subject><dc:subject>renal protection</dc:subject><dc:description xml:lang="en">On the basis of clinical experiences, 5 (five) “Satan Vicious Circles” in diabetic nephropathy (DN) are summarized. These vicious circles should be well recognized to understand the pathogenesis of DN, and to perform its rationale treatment. The 1st “Satan Circle” hypertension –– proteinuria –– glomerular injury –– and then to hypertension again. The 2nd “Satan Circle” GLUT-1 –– glucose –– TGF- β –– and then to GLUT-1 again. The 3rd “Satan Circle” AII –– TGF- β –– PAI-1 –– and then to AII again. The 4th “Satan Circle” AII –– PKC –– AI –– and then to AII again. The 5th “Satan Circle” or the “Deadly Satan Circle” (frequently happens in hemodyalized-patients). Dialysate, Membrane, and AOPP these three components altogether stimulate the production of cytokines (VCAM1, MCP1, etc) –– NADPH oxidase –– increased ROS and RONS production –– activated NFkB/API/MAPK –– and then to cytokines (VCAM1, MCP1, etc) again. ROS and RONS also stimulate the production of MMP9. On the basis of clinical experiences in Surabaya, “DHA-LiCOAR” (Diabetes, Hypertension, Albuminuria – Lipid, Cigarette, Obesity, Antiplatelet, Renal replacement therapy) can be used as practical guideline for the treatment of patients with DN. MARVAL and VALUE are the two landmark studies of valsartan which favours microalbuminuria reduction of patients with DN and lower incidence of new-onset of diabetes, respectively. The results of MARVAL indicate a blood pressure-independent antiproteinuric effects of valsartan (blood pressure-independent effect). Compared with amlodipine, valsartan significantly lowered urinary albumin excretion rate of T2DM with microalbuminuria (-8% in amlodipine vs -44% in valsartan treated, p &lt; 0.001). At 24-weeks, valsartan treated patients showed 29.9% reversion to normoalbuminuria compared with 14.5% in amlodipine treated patients (p &lt; 0.001). In the VALUE study, valsartan showed 23% risk reduction of the new-onset diabetes (p &lt; 0.0001). There was no significant difference in the outcomes in hypertensive patients at high cardiovascular risk treated with regiments based on valsartan or amlodipine. Valsartan (a highlyselective ARB) improved “DHA” (the three essential components), and hence this ARB is in favour of the treatment of patients with diabetic nephropathy.</dc:description><dc:publisher>Airlangga University</dc:publisher><dc:date>2007-04-01</dc:date><dc:type>info:eu-repo/semantics/article</dc:type><dc:identifier>https://journal.unair.ac.id/download-fullpapers-11%20Askandar0702%20_format%20FMI_.pdf</dc:identifier><dc:source>Folia Medica Indonesiana; Vol 43 No 2 (2007)</dc:source><dc:source>2355-8393</dc:source><dc:source>2599-056X</dc:source><dc:language>en</dc:language></oai_dc:dc>